🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs
987

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 987 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Page 13 of 21

  1. PF-06650833

    Pfizer

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  2. PF-07915503, PF-07915503, PF-07915503, Etrasimod Arginine Blue, PF-07915503

    Pfizer Australia Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  3. PH-10 (0.001% Rose Bengal)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Psoriasis

    phase 2 small molecule completed

    1 trial

  4. PH-10 (0.002% Rose Bengal)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Psoriasis

    phase 2 small molecule completed

    1 trial

  5. PH-10 (rose bengal disodium 0.001%)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Plaque Psoriasis

    phase 2 small molecule terminated

    1 trial

  6. PN-943

    Protagonist Therapeutics, Inc

    Ulcerative Colitis Chronic Moderate

    phase 2 small molecule completed

    1 trial

  7. PTG-100

    Protagonist Therapeutics, Inc

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  8. PTM 75 mg Tablets, GS-1427, GS-1427, PTM 100 mg Tablets, GS-1427, PTM 25 mg Tablets

    Gilead Sciences Pty Limited

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  9. Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets, PARACETAMOL, DFV890, Placebo to DFV890 10mg, Placebo to DFV890 25mg, DFV890

    Novartis Pharmaceuticals

    Knee Osteoarthritis

    phase 2 small molecule active

    1 trial

  10. Placebo

    Takeda

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  11. Placebo

    Serono Europe Limited

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  12. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  13. Placebo

    Theravance Biopharma Ireland Umited

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  14. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Radiographic axial spondyloarthritis (as known as ankylosing spondylitis)

    phase 2 small molecule active

    1 trial

  15. Placebo oral capsule

    United Therapeutics Europe Ltd

    Osteoarthritis, Knee

    phase 2 small molecule completed

    1 trial

  16. Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  17. Placebo to match DNTH103, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, DNTH103, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, c

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  18. Placebo to match LY, Mirikizumab, Placebo to Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  19. Placebo: Normal Saline - Solution for injection, Daxdilimab

    Elan Pharma International

    Primary Discoid Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  20. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  21. Prednisolon 5 mg JENAPHARM, SPI-62_DF2, Capsule, hard for oral use as placebo for prednisolone., Film-coated tablet for oral use as placebo for Clofutriben (SPI-62)., SPI-62_DF1

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica (PMR)

    phase 2 small molecule active

    1 trial

  22. R788

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  23. R932333

    RIGEL PHARMACEUTICALS INC

    Lupus Erythematosus, Discoid

    phase 2 small molecule completed

    1 trial

  24. REGN475

    Regeneron UK Limited

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  25. REGN475

    Regeneron UK Limited

    Osteoarthritis

    phase 2 mab terminated

    1 trial

  26. REGN5069

    Regeneron UK Limited

    Osteoarthritis of the Knee

    phase 2 small molecule terminated

    1 trial

  27. RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  28. RO7790121 placebo, RO7790121

    Hoffmann-La Roche

    Moderate to Severe Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  29. Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Psoriasis

    phase 2 small molecule active

    1 trial

  30. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout Arthritis

    phase 2 small molecule active

    1 trial

  31. Rifamycin SV sodium in situ gelling solution matching placebo (80 mL) for rectal administration, Rifamycin 1% in situ gelling solution (80 mL) for rectal administration

    Cosmo Technologies Ltd

    patients with mild to moderate left-sided ulcerative colitis

    phase 2 small molecule active

    1 trial

  32. Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Warm autoimmune hemolytic anemia

    phase 2 small molecule active

    1 trial

  33. Roflumilast

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  34. Roflumilast Cream 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  35. Roflumilast foam 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  36. SAR441566

    Sanofi Pasteur

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  37. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  38. SAR443122

    Sanofi Pasteur

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  39. SCD-044 Tablets 0.3mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 1.0mg, SCD-044 Tablets 0.1mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    moderate to severe plaque psoriasis

    phase 2 small molecule active

    1 trial

  40. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  41. SPY001

    Spyre Therapeutics

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  42. SPY002-072

    Spyre Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  43. SPYPBO-101 Placebo to SPY072, SPY072

    Spyre Therapeutics

    Moderately to Severely Active Rheumatologic Disease

    phase 2 small molecule active

    1 trial

  44. SPYPBO-102, SPYPBO-101, SPY002, SPY002, SPY001-001, SPY001-001

    Spyre Therapeutics

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  45. Sargramostim

    Hospital Authority, Hong Kong

    Pulmonary Alveolar Proteinosis, Autoimmune

    phase 2 small molecule completed

    1 trial

  46. Sarilumab

    Regeneron UK Limited

    Juvenile Idiopathic Arthritis

    phase 2 small molecule completed

    1 trial

  47. Sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Juvenile Idiopathic Arthritis

    phase 2 small molecule active

    1 trial

  48. Sodium Chloride Intravenous Infusion (0.9% w/v), BP, Benlysta 400 mg powder for concentrate for solution for infusion.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

987 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.